Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG 00011

Next Previous
Drug Profile

BG 00011

Alternative Names: BG-00011; STX-100

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrosis; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 05 Dec 2019 Discontinued - Phase-II for Idiopathic pulmonary fibrosis (In the elderly, In adults) in Germany, South Korea, United Kingdom, Spain, Russia, Poland, Netherlands, Italy, Israel, Greece, France, Denmark, Czech Republic, Chile, Belgium, Argentina, Australia and USA (SC) before December 2019 (Biogen pipeline, December 2019)
  • 16 Sep 2019 Biogen terminates the phase II SPIRIT trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA, Argentina, Belgium, Chile, Czech Republic, Denmark, France, Greece, Israel, Italy, Netherlands, Poland, Russia, Spain, United Kingdom, South Korea, Germany (SC), due to safety concerns (NCT03573505)
  • 17 May 2019 Efficacy data from a phase IIa trial in Idiopathic pulmonary fibrosis presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top